RT Journal Article
SR Electronic
T1 Impaired immune signaling and changes in the lung microbiome precede secondary bacterial pneumonia in COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.23.21253487
DO 10.1101/2021.03.23.21253487
A1 Tsitsiklis, Alexandra
A1 Zha, Beth Shoshana
A1 Byrne, Ashley
A1 DeVoe, Catherine
A1 Rackaityte, Elze
A1 Levan, Sophia
A1 Sunshine, Sara
A1 Mick, Eran
A1 Ghale, Rajani
A1 Love, Christina
A1 Tarashansky, Alexander J.
A1 Pisco, Angela
A1 Albright, Jack
A1 Jauregui, Alejandra
A1 Sarma, Aartik
A1 Neff, Norma
A1 Serpa, Paula Hayakawa
A1 Deiss, Thomas J.
A1 Kistler, Amy
A1 Carrillo, Sidney
A1 Ansel, K. Mark
A1 Leligdowicz, Aleksandra
A1 Christenson, Stephanie
A1 Detweiler, Angela
A1 Jones, Norman G.
A1 Wu, Bing
A1 Darmanis, Spyros
A1 Lynch, Susan V.
A1 DeRisi, Joseph L.
A1 ,
A1 Matthay, Michael A.
A1 Hendrickson, Carolyn M.
A1 Kangelaris, Kirsten N.
A1 Krummel, Matthew F.
A1 Woodruff, Prescott G.
A1 Erle, David J.
A1 Rosenberg, Oren
A1 Calfee, Carolyn S.
A1 Langelier, Charles R.
YR 2021
UL http://medrxiv.org/content/early/2021/11/30/2021.03.23.21253487.abstract
AB Secondary bacterial infections, including ventilator-associated pneumonia (VAP), lead to worse clinical outcomes and increased mortality following viral respiratory infections including in patients with coronavirus disease 2019 (COVID-19). Using a combination of tracheal aspirate bulk and single-cell RNA sequencing we assessed lower respiratory tract immune responses and microbiome dynamics in 23 COVID-19 patients, 10 of whom developed VAP, and eight critically ill uninfected controls. At a median of three days (range: 2-4 days) before VAP onset we observed a transcriptional signature of bacterial infection. At a median of 15 days prior to VAP onset (range: 8-38 days), we observed a striking impairment in immune signaling in COVID-19 patients who developed VAP. Longitudinal metatranscriptomic analysis revealed disruption of lung microbiome community composition in patients with VAP, providing a connection between dysregulated immune signaling and outgrowth of opportunistic pathogens. These findings suggest that COVID-19 patients who develop VAP have impaired antibacterial immune defense detectable weeks before secondary infection onset.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding for the COMET cohort enrollment, sample collection and data analysis derived from: K23HL138461-01A1 (CL), K24HL137013 (PGW), F32 HL151117 (AS), R35 HL140026 (CSC), NIAID U19AI077439 (DJE), Chan Zuckerberg Biohub (AB, JLD). The UCSF IMPACC site was funded by NIAID U19AI077439 (DJE). Funding for enrollment of COMET participants not enrolled in IMPACC and for all sample collection and data analysis derived from K23HL138461-01A1 (CL), K24HL137013 (PGW), F32 HL151117 (AS), R35 HL140026 (CSC), and the Chan Zuckerberg Biohub (AB, JLD). Philanthropic support was provided from Mark and Carrie Casey, Julia and Kevin Hartz, Carl Kawaja and Wendy Holcombe, Eric Keisman and Linda Nevin, Martin and Leesa Romo, Three Sisters Foundation, Diana Wagner and Jerry Yang and Akiko Yamazaki.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Studies were approved by the UCSF Institutional Review Board under protocols 17-24056 and 20-30497I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesHost gene expression data are available under NCBI GEO accession number GSE168019 for bulk RNA-seq and GSE168018 for scRNA-seq. Raw microbial sequencing alignments are available from NCBI SRA under BioProject PRJNA704082. Code is available at https://github.com/bspeco/VAPinCOVID19.